Abstract:Choosing antithrombotic therapy for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) is challenging. Oral anticoagulation is indicated to prevent stroke and systemic embolism in patients with atrial fibrillation but has not been shown to prevent stent thrombosis and is generally not indicated for secondary prevention after acute coronary syndrome. 1-3 Dual antiplatelet therapy is proven to reduce the incidence of recurrent ischemic events and stent thrombosis but is less effective in reducing the incidence of cardioembolic stroke associated with atrial fibrillation. 2-4 The combination of antithrombotic agents, particularly triple therapy with oral anticoagulation and dual antiplatelet therapy, increases the risk of bleeding. 5-7 Thus, an oral antithrombotic regimen with an acceptable benefit–risk profile would be useful in the treatment of patients with atrial fibrillation and concomitant acute coronary syndrome or PCI. Regimens including non–vitamin K antagonist oral anticoagulants appear to offer a number of advantages over vitamin K antagonists, including the potential for less bleeding. 8 Two trials evaluated standard or reduced doses of oral anticoagulants (of dabigatran and rivaroxaban, respectively) in patients with atrial fibrillation who were undergoing PCI, and both trials showed a lower incidence of bleeding with new oral anticoagulant regimens without aspirin than with vitamin K antagonist regimens that included aspirin. 9,10 Neither trial was designed to assess whether the lower incidence of bleeding was due to the use of the standard or reduced doses of the new oral anticoagulants or to the removal of aspirin therapy. We conducted the AUGUSTUS trial (a two-by-two factorial, randomized, controlled clinical trial) to assess the safety and efficacy of standard-dose apixaban as compared with a vitamin K antagonist and of low-dose aspirin as compared with placebo, on a background of concomitant P2Y 12 inhibitor therapy for 6 months in patients with atrial fibrillation and recent acute coronary syndrome or PCI. The trial was designed and led by an academic steering committee whose members were responsible for the conduct of the trial. The Duke Clinical Research Institute (DCRI, Durham, NC) was the academic coordinating center. The trial was sponsored by Bristol-Myers Squibb and Pfizer. The trial protocol (available with the full text of this article at NEJM.org) and all subsequent amendments were approved by national regulatory agencies in participating countries and by institutional review boards or ethics committees at participating sites. An independent data and safety monitoring board reviewed unblinded patient-level data at regular intervals during the trial. Although Bristol-Myers Squibb assisted with data management, all the statistical analyses were performed independently at the DCRI. The initial draft of the manuscript was written by the first author and revised on the basis of comments from the other authors. All the authors vouch for the adherence of the trial to the protocol, and the first, second, and last authors vouch for the accuracy and completeness of the data and analysis. No one who is not an author contributed to writing the manuscript. The committee members and participating investigators are listed in the Supplementary Appendix , available at NEJM.org. The trial rationale and design have been published previously. 11 In brief, AUGUSTUS was a prospective, multicenter, two-by-two factorial, randomized clinical trial comparing apixaban with a vitamin K antagonist and comparing aspirin with placebo in patients with atrial fibrillation who had a recent acute coronary syndrome or underwent PCI (or both). Patients who met all the following criteria were eligible for inclusion: an age of at least 18 years; previous, persistent, permanent, or paroxysmal atrial fibrillation and planned long-term use of an oral anticoagulant; recent acute coronary syndrome or PCI; and planned use of a P2Y 12 inhibitor for at least 6 months. Patients who were using anticoagulation for other conditions (e.g., prosthetic valves, venous thromboembolism, and mitral stenosis) were not eligible. Other key exclusion criteria were severe renal insufficiency, a history of intracranial hemorrhage, recent or planned coronary-artery bypass graft surgery, coagulopathy or ongoing bleeding, and contraindication to a vitamin K antagonist, apixaban, all P2Y 12 inhibitors, or aspirin. All the patients provided written informed consent before -Abstract Truncated-

Prevention of ischemic stroke by apixaban in patients with atrial fibrillation

Randomized Study of Efficiency and Safety of Antithrombotic Therapy with Warfarin in Nonvalvular Atrial Fibrillation

New Medicine for Antithrombotic Treatment of Atrial Fibrillation—Who Can Dominate in the Future

Asundexian versus Apixaban in Patients with Atrial Fibrillation

Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinical Trial

Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation from East Asia: a Subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

Meta-analysis evaluating apixaban in patients with atrial fibrillation and end-stage renal disease requiring dialysis

Use of apixaban in adults with congenital heart disease and atrial arrhythmias: The PROTECT-AR study

Antithrombotic Strategies in Atrial Fibrillation After ACS and/or PCI: A 4-Way Comparison From AUGUSTUS

Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review

Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial

Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial

Antithrombotic Strategies According to Age: Insights From the AUGUSTUS Trial

Comparative safety and effectiveness of reduced doses of direct acting oral anticoagulants for stroke prevention in atrial fibrillation.

Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation

Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease

Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial

Anticoagulant Therapy and Outcomes in Patients with Prior or Acute Heart Failure and Acute Coronary Syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 Trial

Comparison of oral anticoagulants for stroke prevention in atrial fibrillation using the UK clinical practice research Datalink Aurum: A reference trial (ARISTOTLE) emulation study

Stroke Prevention in Atrial Fibrillation: Our Current Failures and Required Research